Solid Biosciences Says FDA Grants Fast Track Designation For Gene Therapy Candidate SGT-003
(RTTNews) - Life sciences company Solid Biosciences Inc. (SLDB) announced Thursday that it has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for SGT-003, the company's next-generation Duchenne muscular dystrophy gene therapy candidate.
IND clearance by the FDA for SGT-003 was received in November 2023. The planned Phase 1/2 trial, SGT-003-101, is a first-in-human, open-label, multicenter trial to determine the safety and tolerability of SGT-003 in pediatric patients with DMD at a dose of 1E14vg/kg.
SGT-003 will be administered as a one-time intravenous infusion to patients in two cohorts with a minimum of three patients each, with the potential for cohort expansion. Cohort 1 will study patients aged 4 to < 6 years of age with DMD. Long-term safety and efficacy will be evaluated for a total of 5 years following treatment.
Solid Biosciences Appoints Kevin Tan As New CFO
DAX Extending Recent Weakness
Sensex, Nifty Tumble On Tariff Worries
French Consumer Sentiment Weakest Since 2023
European Shares Decline Amid French Uncertainty
Asian Shares Slip After Trump's Tariff Threats
Indian Rupee Falls To More Than 4-week Low On Tariff Worries
